Elevated levels of procoagulant microparticles in a patient with myocardial infarction, antiphospholipid antibodies and multifocal cardiac thrombosis

被引：28

作者：

Morel O. ^{[1
,2
,3
]}

Jesel L. ^{[1
]}

Freyssinet J.-M. ^{[2
,3
]}

Toti F. ^{[2
,3
,4
]}

机构：

[1] Fédération de Cardiologie, Hôpitaux Universitaires de Strasbourg, 67098 Strasbourg

[2] Université Louis Pasteur, Faculté de Médecine, Institut d'Hématologie et d'Immunolgie, 67085 Strasbourg

[3] Unité 143 INSERM, Hôpital de Bicêtre, 94275 Le Kremlin Bicêtre

[4] Université Paris-Sud, Faculté de Médecine, 94270 Le Kremlin Bicêtre

来源：

Thrombosis Journal | / 3卷 / 1期

关键词：

Acute coronary syndrome; Endothelium;

D O I：

10.1186/1477-9560-3-15

中图分类号：

学科分类号：

摘要：

Circulating procoagulant microparticles (MP) are pathogenic markers of enhanced coagulability associated to a variety of disorders and released from stimulated vascular cells. When derived from endothelial cells, MP were found characteristic of thrombotic propensity in primary antiphospholipid syndrome (APS). The prothrombotic status of a patient with antiphospholipid antibodies (APL), a past history of mesenteric vein thrombosis and presenting myocardial infarction and extensive intracardiac thrombosis was examined by measurement of circulating procoagulant MP. MP of platelet and endothelial origins were highly elevated with respect to values detectable in patients with myocardial infarction and no history of APS (6- and 3-fold elevation, respectively) or in healthy volunteers (13- and 25-fold elevation, respectively). In this particular patient, with moderate APL titer, a drastic release of procoagulant MP could have contributed to thrombus growth and the development of extensive intracardiac thrombosis. © 2005 Morel et al., licensee BioMed Central Ltd.

引用

页数：15

共 25 条

[1]

Arnout J., Vermylen J., Current status and implications of autoimmune antiphospholipid in relation to thrombotic disease, Journal of Thrombosis and Haemostasis, 1, pp. 931-942, (2003)

[2]

Harpaz D., Glikson M., Sidi Y., Hod H., Successful thrombolytic therapy for acute myocardial infarction in a patient with the antiphospholipid antibody syndrome, Am. Heart J., 122, pp. 1492-1495, (1991)

[3]

Morton K.E., Gavaghan T.P., Krilis S.A., Daggard G.E., Baron D.W., Hickie J.B., Chesterman C.N., Coronary artery bypass graft failure - An autoimmune phenomenon?, Lancet, 2, 8520, pp. 1353-1357, (1986)

[4]

Musuraca G., Imperadore F., Terraneo C., De Girolamo P., Cemin C., Bonmassari R., Vergara G., Successful treatment of post-exertion acute myocardial infarction by primary angioplasty and stenting in a patient with antiphospholipid antibody syndrome, Blood Coagul. Fibrinolysis, 15, pp. 95-98, (2004)

[5]

Triplett D.A., Antiphospholipid antibodies, Arch. Pathol. Lab. Med., 126, pp. 1424-1429, (2002)

[6]

Combes V., Simon A.C., Grau G.E., Arnoux D., Camoin L., Sabatier F., Mutin M., Sanmarco M., Sampol J., Dignat-George F., In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant, J. Clin. Invest., 104, pp. 93-102, (1999)

[7]

Bordron A., Dueymes M., Levy Y., Jamin C., Leroy J.P., Piette J.C., Shoenfeld Y., Youinou P.Y., The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis, J. Clin. Invest., 101, pp. 2029-2035, (1998)

[8]

VanWijk M.J., VanBavel E., Sturk A., Nieuwland R., Microparticles in cardiovascular diseases, Cardiovasc. Res., 59, pp. 277-287, (2003)

[9]

Morel O., Toti F., Hugel B., Freyssinet J.M., Cellular microparticles: A disseminated storage pool of bioactive vascular effectors, Curr. Opin. Hematol., 11, pp. 156-164, (2004)

[10]

Singh N., Gemmell C., Daly P.E.Y., Elevated platelet-derived microparticle levels during unstable angina, Can. J. Cardiol., 11, pp. 1015-1021, (1995)

← 1 2 3 →